Trials / Unknown
UnknownNCT03466671
A Trial of TTA-121 on Autism Spectrum Disorder
An Early Phase II Trial for Efficacy and Safety of TTA-121 on Autism Spectrum Disorder
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Hamamatsu University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 54 Years
- Healthy volunteers
- Not accepted
Summary
To test efficacy and safety of a novel nasal spray of oxytocin on social deifies in autism spectrum disorder, and To compare effect sizes of different doses
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTA-121 | A nove intranasal spray of oxytocin and placebo |
Timeline
- Start date
- 2018-02-27
- Primary completion
- 2020-03-16
- Completion
- 2020-03-30
- First posted
- 2018-03-15
- Last updated
- 2019-12-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03466671. Inclusion in this directory is not an endorsement.